Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS) in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs)

被引：0
|
作者：
Kunstfeld, R. [1 ]
Zloty, D. [2 ]
Tang, J. [3 ]
Basset-Seguin, N. [4 ]
Bissonnette, R. [5 ]
Grob, J. -J. [6 ]
Maher, I. [7 ]
Bergstrom, D. [8 ]
Gilberg, F. [8 ]
Dreno, B. [9 ]
Rogers, G. [10 ]
Schadendorf, D. [11 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ British Columbia, Vancouver, BC, Canada
[3] Stanford Univ, La Jolla, CA USA
[4] Hop St Louis, Paris, France
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Aix Marseille Univ, Hop Timone, APHM, Marseille, France
[7] St Louis Univ, Sch Med, St Louis, MO USA
[8] Hoffman La Roche Ltd, Basel, Switzerland
[9] Univ Nantes, Nantes, France
[10] Tufts Univ, Sch Med, Boston, MA 02111 USA
[11] Univ Klinikum Essen, Essen, Germany
来源：
MELANOMA RESEARCH | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P134
引用
收藏
页码：E78 / E78
页数：1
相关论文
共 49 条
  • [21] A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Chowdhury, Simon
    McDermott, David F.
    Voss, Martin Henner
    Hawkins, Robert E.
    Aimone, Paola
    Voi, Maurizio
    Isabelle, Naeije
    Wu, Vi
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
    Dummer, Reinhard
    Migden, Michael Robert
    Guminski, Alexander
    Gutzmer, Ralf
    Kudchadkar, Ragini Reiney
    Lewis, Karl D.
    Dirix, Luc
    Combemale, Patrick
    Trefzer, Uwe
    Loquai, Carmen
    Kaatz, Martin
    Chang, Anne L. S.
    Stratigos, Alexander
    Plummer, Elizabeth R.
    Mone, Manisha
    Castro, HenryJ.
    Yi, Tingting
    Sellami, Dalila B.
    Lear, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).
    Voss, Martin Henner
    Coates, Andrea
    Garmey, Edward Graeme
    Haas, Naomi B.
    Hutson, Thomas
    Keefe, Stephen Michael
    Motzer, Robert
    Piscitelli, Anthony
    Vogelzang, Nicholas J.
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
    Lear, John T.
    Hauschild, Axel
    Stockfleth, Eggert
    Squittieri, Nicholas
    Basset-Seguin, Nicole
    Dummer, Reinhard
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 117 - 121
  • [25] Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
    Lear, J. T.
    Migden, M. R.
    Lewis, K. D.
    Chang, A. L. S.
    Guminski, A.
    Gutzmer, R.
    Dirix, L.
    Combemale, P.
    Stratigos, A.
    Plummer, R.
    Castro, H.
    Yi, T.
    Mone, M.
    Zhou, J.
    Trefzer, U.
    Kaatz, M.
    Loquai, C.
    Kudchadkar, R.
    Sellami, D.
    Dummer, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 372 - 381
  • [26] A phase 1/2 study to evaluate the efficacy and safety of HB0025 monotherapy for patients (pts) with advanced renal cell carcinoma (RCC)
    Qu, Yuan-Yuan
    Ye, Dingwei
    Bian, Xiaojie
    Han, Weiqing
    Liu, Kan
    Dai, Tao
    Sun, Yuping
    Bian, Jiasheng
    Dang, Qi
    Sun, Meili
    Wang, Zhen
    Zhang, Jian
    Zhou, Huan
    Gao, Zhenyuan
    Zhu, Xiangyang
    Yang, Yongmin
    Chen, Juan
    Yang, Yang
    Wang, Junning
    Cai, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Primary Analysis of Phase-2-Results for Cemiplimab in Patients (pts) with locally advanced Basal Cell Carcinoma (laBCC) who progress or cannot tolerate Hedgehog Inhibitors (HHI)
    Stratigos, A. J.
    Sekulic, A.
    Peris, K.
    Bechter, O.
    Dutriaux, C.
    Kaatz, M.
    Lewis, K. D.
    Basset-Seguin, N.
    Chang, A. L. S.
    Dalle, S.
    Orland, A. Fernandez
    Licitra, L.
    Robert, C.
    Ulrich, C.
    Hauschild, A.
    Migden, M. R.
    Dummer, R.
    Li, S.
    Bowler, T.
    Fury, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 41 - 42
  • [28] Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
    Dummer, R.
    Guminksi, A.
    Gutzmer, R.
    Lear, J. T.
    Lewis, K. D.
    Chang, A. L. S.
    Combemale, P.
    Dirix, L.
    Kaatz, M.
    Kudchadkar, R.
    Loquai, C.
    Plummer, R.
    Schulze, H. -J.
    Stratigos, A. J.
    Trefzer, U.
    Squittieri, N.
    Migden, M. R.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (06) : 1369 - 1378
  • [29] A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis
    Fortin, A.
    Cmelak, A.
    Mesia, R.
    Minn, H.
    Chan, A. T. C.
    Yunes, A. C.
    Merlano, M. C.
    Singh, S.
    Smitt, M.
    Henke, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 476 - 476
  • [30] A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases.
    Verzoni, Elena
    Grassi, Paolo
    Montone, Rosanna
    Maggi, Claudia
    Cognetti, Francesco
    Milella, Michele
    Bearz, Alessandra
    Ortega, Cinzia
    Morelli, Franco
    Chiuri, Vincenzo Emanuele
    Necchi, Andrea
    De Braud, Filippo G.
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345